Kremlin spokesman Dmitry Peskov has said demand for Sputnik V significantly exceeds Russia s domestic production capacity. To boost production, the Russian Direct Investment Fund, which bankrolled Sputnik V, has signed agreements with multiple drug makers in other countries, such as India, South Korea, Brazil, Serbia, Turkey, Italy and others. There are few indications, however, that manufacturers abroad, except for those in Belarus and Kazakhstan, have made any large amounts of the vaccine so far. Airfinity, a London-based science analytics company, estimates Russia agreed to supply some 630 million doses of Sputnik V to over 100 countries, with only 11.5 million doses exported so far.
Russia, facing lags, turns to China to produce Sputnik shots
Business Related
Better
FILE - In this Dec. 10, 2020, file photo, a Russian medical worker prepares a shot of Russia s Sputnik V coronavirus vaccine in Moscow. Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot. (AP Photo/Pavel Golovkin, File)
TAIPEI, Taiwan – Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot.
Russia has announced three deals totalling 260 million doses with Chinese vaccine companies in recent weeks. It’s a decision that could mean quicker access to a shot for countries in Latin America, the Middle East, and Africa that have ordered Russia’s vaccine, as the U.S. and the European Union focus mainly on domestic vaccination needs.
.... .... .... .... .... .... .... .... .... .... .... .... .... .... .... .... .... ....
TAIPEI, Taiwan Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot.
Russia has announced three deals totaling 260 million doses with Chinese vaccine companies in recent weeks. It’s a decision that could mean quicker access to a shot for countries in Latin America, the Middle East, and Africa that have ordered Russia’s vaccine, as the U.S. and the European Union focus mainly on domestic vaccination needs.
Earlier criticism about Russia’s vaccine have been largely quieted by data published in the British medical journal The Lancet that said large-scale testing showed it to be safe, with an efficacy rate of 91%.
Russia Unlikely to Meet Promised 630M Target for COVID Vaccine Doses, Now Partnering with China
On 5/3/21 at 1:09 PM EDT
A London-based science analytics company, Airfinity, told the
Associated Press that it estimates Russia agreed to give 630 million doses of its homegrown vaccine to more than 100 countries but has exported only 11.5 million doses so far.
Moscow announced three deals totaling 260 million doses with Chinese vaccine companies in the past few weeks. The doses could reach countries in Latin America, the Middle East and Africa more quickly as a result of the partnership.
The partnership is also a benefit for both Russian and Chinese interests. Rasmus Bech Hansen, founder and CEO of Airfinity, said Russia is very ambitious and unlikely to meet their full targets.